Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

TL;DR: The authors sought to quantify the potential financial impact of restrictions in never events and periprocedural HAC billing on a tertiary neurosurgery facility and found potentially significant reductions in physician and facility billing.

TL;DR: Data are emerging that the antithrombotics, and particularly low-molecular-weight heparins, may exert an antitumor effect which could contribute to improved survival in cancer patients when given for long-term prophylaxis.

TL;DR: Morbidly obese patients require smaller UFH infusion rates per kilogram actual body weight compared to patients with lower body mass indices, and UFH dosing recommendations should be modified to reflect body mass index classification.

TL;DR: This work intends to provide evidence-based guidelines for diagnosis and treatment of lower extremity deep vein thrombosis by multidisciplinary consensus and are the result of a close collaboration between interventional radiologists and vascular surgeons.

TL;DR: In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thrombosis without increasing therisk of bleeding.

TL;DR: Guyatt et al. as mentioned in this paper presented the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) and provided specific management recommendations for the first 1 or 2 days for most individuals.

TL;DR: The clinical course of a first episode of symptomatic deep venous thrombosis in a large consecutive series of patients who had long-term follow-up was assessed and the potential risk factors for these three outcomes were evaluated.

TL;DR: It is shown that patients with symptomatic proximal DVT may benefit from fitted compression stockings for at least 3 months to reduce the incidence of the postthrombotic syndrome, and patients with VTE who receive adequate anticoagulation generally do not die of recurrent disease.